Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Trevi Therapeutics, Inc. on January 14, 2022, regarding an event that occurred on January 10, 2022. The Company is a Delaware corporation with its principal executive offices in New Haven, Connecticut, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "TRVI".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a regulatory compliance issue regarding the Company's stock price.
Material Changes and Events
On January 10, 2022, the Company received a deficiency letter from the Nasdaq Listing Qualifications Department. The notification stated that for the last 30 consecutive business days, the bid price for the Company's common stock had closed below the $1.00 per share minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-calendar-day compliance period, ending on July 11, 2022, to regain compliance.
- Regaining Compliance: To cure the deficiency within the initial period, the stock must close at $1.00 or more for a minimum of 10 consecutive business days.
- Alternative Options: If the Company fails to regain compliance by the deadline, it may be eligible for an additional 180-day period by transferring its listing to the Nasdaq Capital Market, provided it meets other listing standards. This may require a reverse stock split.
- Delisting Risk: If the Company cannot cure the deficiency or does not apply for a transfer, the stock may be subject to delisting. The Company may appeal such a determination, though success is not assured.
- Management Intent: The Company intends to monitor the closing bid price and may consider a reverse stock split if appropriate, though there is no assurance of regaining compliance.
Investor Verification Checklist
- Verify the current closing bid price of TRVI common stock to assess proximity to the $1.00 threshold.
- Monitor the Company's stock price performance over the next 10 consecutive business days to determine if immediate compliance is achieved.
- Review future filings for announcements regarding a potential reverse stock split or application to transfer to the Nasdaq Capital Market.
- Check for any subsequent correspondence from Nasdaq regarding the extension of the compliance period or delisting notices.